Menu
Annual · values2025202420232022202120202019
Operating Cash Flow-8.27 M USD-18.32 M USD-7.29 M USD-11.22 M USD-725618 USD-218713 USD
Depreciation & Amortization27058 USD27923 USD25049 USD25048 USD16782 USD
Stock-Based Compensation595368 USD168850 USD155721 USD301116 USD470878 USD
Capital Expenditures19171 USD131963 USD
Cash Flow from Investing-19171 USD25.74 M USD-74.04 M USD
Cash Flow from Financing12.47 M USD12.85 M USD14.03 M USD15.20 M USD-24.95 M USD74.27 M USD
Dividends Paid
Stock Buybacks35.50 M USD
Free Cash Flow-18.34 M USD-857581 USD

Revelation Biosciences Inc. is a biotechnology company focused on developing diagnostic and therapeutic products to address respiratory and infectious diseases. Their primary function is to innovate in the field of healthcare with novel solutions that can detect and combat prevalent health threats. Notably, Revelation Biosciences is involved in creating point-of-care diagnostic tests that aim to quickly and efficiently identify infections, enabling timely and informed medical decisions. The company also pursues therapeutic development to improve treatment outcomes for patients suffering from respiratory ailments. Within the financial market, Revelation Biosciences contributes to the healthcare and biotech sectors, representing the intersection of technology and medicine to address critical health challenges. With a commitment to research and development, Revelation Biosciences is a key player in improving diagnostic and therapeutic approaches, thus enhancing healthcare delivery and patient care globally.